Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,792 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Sham Treatment Clear all

Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions: ASP2138, Pembrolizumab, Oxaliplatin, Capecitabine, Folinic acid, 5-FU, Placebo for ASP2138, Placebo for Pembrolizumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Saint Louis Park, Minnesota

Conditions: Intraventricular Hemorrhage, Periventricular Leukomalacia, Brain Injury, Renal Injury
Interventions: Indomethacin, delay in umbilical cord clamp at birth, placebo infusion, immediate cord clamp at birth; Drug · Procedure
Lead sponsor: Hong Huang; Other
Eligibility: 24 Weeks to 30 Weeks
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Cell Migration, Cell Invasion, Exercise Recovery
Interventions: Melatonin, Placebo; Dietary Supplement
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: D-serine, placebo, Sensory Based remediation paradigm; Drug · Behavioral
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Mild Cognitive Impairment
Interventions: Circadian-Effective Light, Rhythmic Light, Placebo Light, Placebo Rhythmic Light; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 55 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Menands, New York • New York, New York

Conditions: Systemic Lupus Erythematosus
Interventions: Epratuzumab, Placebo; Biological · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 16 more

Conditions: Muscle Fatigue Caused by Repetitive Muscle Exercise
Interventions: Placebo, ATP; Dietary Supplement
Lead sponsor: Metabolic Technologies Inc.; Industry
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: COVID-19, Corona Virus Infection, ARDS, Acute Respiratory Distress Syndrome
Interventions: Hydroxychloroquine, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Minneapolis, Minnesota

Conditions: Erectile Dysfunction, Testosterone Deficiency, Diabetes
Interventions: Sildenafil citrate (open label), Testosterone gel, Placebo gel; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Migraine
Interventions: Treximet, Placebo; Drug
Lead sponsor: Premiere Research Institute; Other
Eligibility: 12 Years to 17 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 4
States / cities: West Palm Beach, Florida • Cincinnati, Ohio • Dallas, Texas + 1 more

Conditions: Hearing Loss
Interventions: Attention to Variability (ATV), Placebo; Behavioral · Other
Lead sponsor: Harvard University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Stroke
Interventions: Novel rTMS Approach, Sham rTMS Approach; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Long COVID, Long COVID-19, Long COVID19
Interventions: BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE, tDCS-active, tDCS-sham; Other · Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 24
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 20 more

Conditions: Obesity
Interventions: Behavioral Treatment, Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]; Behavioral · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myocardial Bridging
Interventions: Nebivolol, Diltiazem, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Rheumatoid Arthritis
Interventions: Plant-based diet, Supplement; Other
Lead sponsor: Physicians Committee for Responsible Medicine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Schizophrenia
Interventions: Transcranial Direct Current Stimulation; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 35 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Obesity, Diabetes Mellitus, Type 2
Interventions: nutrition education plus active supplement, nutrition education plus inactive supplement; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 13 Years to 17 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Migraine
Interventions: Omega 3 Polyunsaturated Fats, Matching Placebo; Dietary Supplement · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 10 Years to 17 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Osteoarthritis of the Knee, Degenerative Osteoarthritis, Knee Pain Chronic
Interventions: Ibuprofen and PRP, Acetaminophen and PRP, Placebo and PRP; Combination Product
Lead sponsor: QC Kinetix LLC; Industry
Eligibility: 50 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Bronchopulmonary Dysplasia
Interventions: Furosemide Cohort 1, Furosemide Cohort 2, Furosemide Cohort 3, Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 7 Days to 28 Days
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 21
States / cities: Little Rock, Arkansas • Loma Linda, California • Jacksonville, Florida + 17 more

Conditions: Atopic Dermatitis, Food Allergies
Interventions: B. infantis, Placebo; Drug
Lead sponsor: Emanual Maverakis, MD; Other
Eligibility: 1 Day to 7 Days
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Microvascular Coronary Artery Disease
Interventions: SAR407899, Placebo, Adenosine, Regadenoson, 13N-ammonia, 82Rubidium; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Jacksonville, Florida • Wellington, Florida + 3 more

Conditions: Stress Disorders, Post-Traumatic
Interventions: Magnetic EEG/ECG-guided Resonance Therapy, Sham; Device
Lead sponsor: Wave Neuroscience; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury

This Repeated Measures Parallel-group Investigation Will Examine the Influence of Short-term Melatonin Supplementation (5mg, 3 x Day for 72 Hours) on Cellular Responses, Functional Performance and Recovery Following an Acute Bout of Dynamic Resistance Exercise in Resistance Trained Men and Women

N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia

Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients

Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

Study to Examine the Effects of ATP Supplementation on Muscle Excitability and Reaction Time During and Following a Repeated Sprint Bout

Pre-exposure Prophylaxis for SARS-Coronavirus-2

Effect of Testosterone in Men With Erectile Dysfunction

Treximet Early Intervention Adolescent Migraine

Mindfulness Intervention and Symptom Variability in Hearing

A Novel Brain Stimulation for Bimanual Motor Function and Control in Chronic Stroke

RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

A Nutrition Intervention for Arthritis -3 (WCCR-ARTH3)

The Effects of tDCS on the Neuronal Mechanisms of Cognitive Control in Schizophrenia

Supplements for Controlling Resistance to Insulin

Omega-3 Supplementation for Pediatric Migraine

Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee Osteoarthritis

Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)

Probiotic Supplementation in Breastfed Newborn Infants

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

Trial to Evaluate Efficacy of Magnetic Resonant Therapy (MRT) in PTSD